|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:acquisitionYear
|
2019
|
|
gptkbp:approvalYear
|
2018
2020
|
|
gptkbp:FDAApproved
|
gptkb:larotrectinib
gptkb:selpercatinib
|
|
gptkbp:focus
|
oncology
cancer therapeutics
|
|
gptkbp:foundedYear
|
2013
|
|
gptkbp:founder
|
gptkb:Alexis_Borisy
gptkb:David_Hyman
gptkb:Jacob_Van_Naarden
gptkb:Joshua_Bilenker
|
|
gptkbp:headquartersLocation
|
gptkb:Stamford,_Connecticut,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Loxo Oncology
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:notableAchievement
|
developed first TRK inhibitor approved by FDA
|
|
gptkbp:notableProduct
|
gptkb:larotrectinib
gptkb:selpercatinib
|
|
gptkbp:numberOfEmployees
|
~60
|
|
gptkbp:parentCompany
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:specialty
|
targeted cancer therapies
|
|
gptkbp:status
|
acquired
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:LOXO
delisted
|
|
gptkbp:website
|
https://www.loxooncology.com/
|
|
gptkbp:bfsParent
|
gptkb:礼来
|
|
gptkbp:bfsLayer
|
5
|